학술티모카지노 샘플(의학논문티모카지노)

원문 만성 신질환자에서 빈혈에 대한 페기네사타이드(peginesatide)의 효능은 2상 임상시험을 통해 입증되었다. 시약투여 전 12주 동안 투석과 조혈자극제 치료를 모두 안 받은 환자들이 초기 페기네사타이드 용량(체중대비용량, 절대용량)과 투여경로(정맥주사, 피하주사), 투여빈도(2주 1회, 4주 1회)에 따라 10군으로 순차적으로 배정되었다. 전체 환자 중에서는 96%의 환자에서 헤모글로빈 반응이 나타났다. 헤모글로빈의 증가에서는 용량반응관계가 보였다. 피하주사나 정맥주사를 유사한 용량으로 투여했을 경우 두 환자군에서 비슷한 수준의 헤모글로빈 반응이 나타났다. 헤모글로빈의 빠른 상승과 1 g/dL 이상의 헤모글로빈 변동은 4주 1회 투여하는 환자보다 2주 1회 투여하는 환자에서 더 많이 일어나는 경향이 있었다. 본 연구는 비투석 만성 신질환자에서 4주 1회 페기네사타이드를 투여하는 것이 헤모글로빈 수치를 증가시키거나 유지하는 데 효과적이라는 것을 처음으로 입증했다는 점에서 의미가 있다. 에포에틴 알파(epoetin alfa) 치료 받고 있는 투석 환자는 성공적으로4주 1회의 페기네사타이드 치료로 바꿀 수 있다는 것이 3상 임상시험을 통해 밝혀졌다.
Reference: Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3377433/

원문티모카지노 The efficacy of peginesatide in the treatment of anemia in 티모카지노 with CKD is proven in a Phase 2 clinical trial. 티모카지노 who had received neither dialysis nor an erythropoiesis-stimulating agent in the 12 weeks prior to the administration of the test drug were sequentially assigned to one of ten groups according to initial dose of peginesatide (weight-based vs. fixed dose), administration route (intravenous vs. subcutaneous injection), and frequency (once every-2-week vs. every-4-week dosing). In all 티모카지노, 96% showed a hemoglobin (Hb) response, and Hb increase showed a dose-response relationship. When similar dose was given by intravenous or subcutaneous injection, both patient groups showed a similar level of Hb response. There was a tendency for the 티모카지노 who received once every-4-week dosing to show more rapid Hb elevation and fluctuation in Hb over 1 g/dL than in 티모카지노 who received once every-2-week dosing. The significance of the present study is that it was the first study to prove that once every-4-week dosing of peginesatide is more effective in increasing or maintaining Hb levels in non-dialysis CKD 티모카지노. It was shown in a Phase 3 clinical trial that dialysis 티모카지노 being treated with epoetin alfa can successfully transition to once every-4-week dosing of peginesatide.

티모카지노본 검토 The efficacy of peginesatide in the treatment of anemia in 티모카지노 with chronic kidney disease (2Sitemap is) has been proven in a Phase 2 clinical trial. 티모카지노 who had received neither dialysis nor an erythropoiesis-stimulating agent in the 12 weeks prior to the administration of the test drug were sequentially assigned to one of ten groups according to initial dose of peginesatide (weight-based vs. fixed dose), administration route (intravenous vs. subcutaneous injection), and administration frequency (once every-2-week vs. every-4-week dosing). InAmong all 티모카지노, 96% showed a hemoglobin (Hb) response, and Hbthe increase in Hb showed a dose-response relationship. When similar dose was givenadministered by intravenous or subcutaneous injection, both patient groups showed a similar level of Hb response. There was a tendency for the 티모카지노 who received once every-4-week dosing to show more rapid Hb elevation and fluctuation in Hb over 1 g/dL than in 티모카지노 who received once every-2-week dosing. The significance of the present study is that it was the first study to prove that once every-4-week dosing of peginesatide is more effective in increasing or maintaining Hb levels in non-dialysis CKD 티모카지노. It was shown in a Phase 3 clinical trial that dialysis 티모카지노 being treated with epoetin alfa can successfully transition to once every-4-week dosing of peginesatide.

프리미엄교정 This24영문교정 study aimed to test the efficacy of peginesatide in the treatingment of anemia in 티모카지노 with chronic kidney disease (CKD) has been proven in by using a Phase 2 clinical trial. Our study population consisted of 25|25|atients who had were not 2Editage for Labs on dialysis nor or received an erythropoiesis-stimulating agent in the 12 weeks prior to the administeringration of the test drug. were The population was divided intosequentially assigned to one of ten groups cohorts according to that differed in the initial dose of peginesatide (weight-based vs. fixed dose), administration route (intravenous vs. subcutaneous injection), and administration frequency (once every-2-week vs. every-4-week dosing); each patient was sequentially assigned to a cohort. Among all 티모카지노, 96% showed a hemoglobin (Hb) response, and the increase in Hb showed 2신규n evident dose-response relationship was observed. The Hb responses were similar WWhen similar the 30지인추천s was administered by intravenous or and subcutaneous injections, were similar both patient groups showed a similar level of Hb response. There was a tendency for t3|he 티모카지노 who received once every-4-week dosing tended to show more rapid Hb elevation and fluctuation in Hb of over 1 g/dL than in the 티모카지노 who received once every-2-week dosing. To the best of our knowledge, The significance of the present study is that it was the first study to prove that once every-4-week dosing of peginesatide is more effective in increasing or maintaining Hb levels in non-dialysis 2Sitemap 티모카지노 not undergoing dialysis. It was shown in a2신규 Phase 3 clinical trial showed that dialysis 티모카지노 being treated with epoetin alfa can successfully transition to once every-4-week dosing of peginesatide.

34지인추천 This study aimed to test the efficacy of peginesatide in treating anemia in 티모카지노 with chronic kidney disease (CKD) by using a Phase 2 clinical trial. Our study population consisted of 티모카지노 who were not on dialysis or received an erythropoiesis-stimulating agent in the 12 weeks prior to administering the test drug. The population was divided into ten cohorts that differed in the initial dose of peginesatide (weight-based vs. fixed dose), administration route (intravenous vs. subcutaneous injection), and administration frequency (every-2-week vs. every-4-week dosing); each patient was sequentially assigned to a cohort. Among all 티모카지노, 96% showed a hemoglobin (Hb) response, and an evident dose-response relationship was observed. The Hb responses were similar when the doses administered by intravenous and subcutaneous injections were similar. The 티모카지노 who received every-4-week dosing tended to show more rapid Hb elevation and fluctuation in Hb of over 1 g/dL than the 티모카지노 who received every-2-week dosing. To the best of our knowledge, the present study is the first to prove that every-4-week dosing of peginesatide is more effective in increasing or maintaining Hb levels in CKD 티모카지노 not undergoing dialysis. A Phase 3 clinical trial showed that dialysis 티모카지노 being treated with epoetin alfa can successfully transition to every-4-week dosing of peginesatide.

3학술티모카지노 A Phase 2 clinical trial showed thatThe efficacy of peginesatide was efficacious in the treatingment of anemia in 티모카지노 with chronic kidney disease (CKD) has been proven in a Phase 2 clinical trial3Editage for Labs had were not 2Editage for Labs on dialysis nor or received an erythropoiesis-stimulating agent in the 12 weeks prior to the administration of the test drug were sequentially assigned to one of ten groups cohorts according to the initial dose of peginesatide (weight-based vs. fixed dose), administration route (intravenous vs. subcutaneous injection), and administration frequency (once every-2-week vs. every-4-week dosing). Among all 티모카지노, 96% showed a hemoglobin (Hb) response, and the increase in Hb showed 2신규n evident dose-response relationship was observed. When similar the doses was administered by intravenous or and subcutaneous injections were similar, both the patient groupscohorts showed a similar level of Hb response. There was a tendency for the 티모카지노 who received once every-4-week dosing to show more rapid Hb elevation and fluctuation in Hb of over 1 g/dL than in 티모카지노 who received once every-2-week dosing. The significance of the present study is that it wa40|s the first study to prove that once every-4-week dosing of peginesatide is more effective in increasing or maintaining Hb levels in non-dialysis CKD 티모카지노. It was shown in a Phase 3 clinical trial that dialysis 티모카지노 being treated with epoetin alfa can successfully transition to once every-4-week dosing of peginesatide.

34지인추천 A Phase 2 clinical trial showed that peginesatide was efficacious in treating anemia in 티모카지노 with chronic kidney disease (CKD). 티모카지노 who were not on dialysis or received an erythropoiesis-stimulating agent in the 12 weeks prior to the administration of the test drug were sequentially assigned to one of ten cohorts according to the initial dose of peginesatide (weight-based vs. fixed dose), administration route (intravenous vs. subcutaneous injection), and administration frequency (every-2-week vs. every-4-week dosing). Among all 티모카지노, 96% showed a hemoglobin (Hb) response, and an evident dose-response relationship was observed. When the doses administered by intravenous and subcutaneous injections were similar, the cohorts showed a similar level of Hb response. There was a tendency for the 티모카지노 who received every-4-week dosing to show more rapid Hb elevation and fluctuation in Hb of over 1 g/dL than in 티모카지노 who received every-2-week dosing. The significance of the present study is that it is the first study to prove that every-4-week dosing of peginesatide is more effective in increasing or maintaining Hb levels in non-dialysis CKD 티모카지노. It was shown in a Phase 3 clinical trial that dialysis 티모카지노 being treated with epoetin alfa can successfully transition to every-4-week dosing of peginesatide.